Classes
DEA Class; Rx
Common Brand Names; Zaroxolyn
- Diuretics, Other
Description
Oral quinazoline diuretic; used for edema and HTN; sulfonamide derivative; may produce diuresis in patients with impaired renal function; Zaroxolyn® is a formulation with relatively slow and incomplete absorption. Mykrox®, a more rapidly absorbed product with enhanced bioavailability, is no longer available in the US.
Indications
Indicated for the treatment of hypertension.
Contraindications
Documented hypersensitivity to metolazone or sulfonamides
Anuria
Hepatic coma or precoma
Adverse Effects
- Chest pain
- Depression
- Dizziness
- Drowsiness
- Electrolyte abnormalities
- Glucosuria
- Gout attacks
- Headache
- Hemoconcentration
- Hepatotoxicity
- Hyperuricemia
- Hypochloremic alkalosis
- Hypokalemia
- Hypomagnesemia
- Hyponatremia
- Hypophosphatemia
- Hyperglycemia
- Hypercalcemia
- Impotence
- Increased blood urea nitrogen (BUN)
- Joint pain
- Leukopenia
- Lightheadedness
- Necrotizing angiitis
- Neuropathy
- Nocturia
- Orthostatic hypotension
- Palpitations
- Pancreatitis
- Restlessness
- Stevens-Johnson syndrome
- Syncope
- Toxic epidermal necrolysis
- Urticaria
- Venous thrombosis
- Volume depletion
Warnings
Use with caution in diabetes mellitus, hypercholesterolemia, hyperuricemia or gout, hypotension, systemic lupus erythematosus (can cause exacerbation or activation), previous sympathectomy, liver disease
Avoid concurrent use with lithium (reduction of lithium dosage by 50% may be necessary)
May aggravate digitalis toxicity
Photosensitization may occur
Severe hypokalemia and/or hyponatremia may occur following initial doses; hypochloremic alkalosis, hypercalcemia, and/or hypomagnesemia may also occur; correct electrolyte imbalance before initiating therapy
Angioedema and other hypersensitivity reactions may occur, including bronchospasm with or without history of allergy or asthma
Patients allergic to sulfa may show cross-sensitivity; however, recent studies on allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or, at the very least, this potential is extremely low
May deleteriously alter lipid/glucose metabolism
Mykrox not therapeutically interchangeable with Zaroxolyn
Risk of male sexual dysfunction
Monitor for hypotension if administered concurrently with hypotensive agents
If azotemia and oliguria worsen during treatment in patients with renal disease, discontinue therapy
In primary adrenal insufficiency, avoid use of diuretics to treat hypertension; adjustment of glucocorticoid/mineralocorticoid therapy and/or use of other antihepertensive agents preferred
Therapy with metolazone may render the patients volume depleted if given in the morning of surgery; blood pressure may be labile during general anesthesia
Pregnancy and Lactation
Pregnancy
Drug appears in cord blood and crosses placenta; hypokalemia, hypoglycemia, jaundice, thrombocytopenia, and hyponatremia reported in fetus or newborn following maternal use of thiazide diuretics
Lactation
Drug excreted in breast milk; decision on whether to discontinue nursing or discontinue drug should be based on importance of treatment to mother
Maximum Dosage
5 mg/day PO Zaroxolyn or generic equivalent for hypertension; 20 mg/day PO Zaroxolyn for edema; higher single doses such as 150 mg PO of Zaroxolyn have been used in the treatment of patients with chronic renal failure.
5 mg/day PO Zaroxolyn for hypertension; 20 mg/day PO Zaroxolyn for edema; higher single doses such as 150 mg PO of Zaroxolyn have been used in the treatment of patients with chronic renal failure.
No maximum dosage information is available.
0.4 mg/kg/day PO Zaroxolyn or generic equivalent.
How supplied
Metolazone
tablets
- 2.5mg
- 5mg
- 10mg